Edition:
United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

17.00USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$17.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
180,394
52-wk High
$17.70
52-wk Low
$9.30

Chart for

About

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $792.83
Shares Outstanding(Mil.): 46.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-ING Groep NV Reports 6.70 Pct Passive Stake In Sucampo Pharmaceuticals As Of Dec 7 - SEC Filing

* REPORTS A 6.70 PCT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DEC 7 - SEC FILING Source text: (http://bit.ly/2yseEW4) Further company coverage:

Dec 14 2017

BRIEF-Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals

* LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING Source text : [http://bit.ly/2jz2syj] Further company coverage:

Dec 08 2017

Sucampo weighs sale after fielding takeover interest: Bloomberg

Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

Dec 07 2017

Sucampo weighs sale after fielding takeover interest -Bbg

Dec 7 Sucampo Pharmaceuticals Inc is considering selling itself after receiving takeover interest, Bloomberg reported on Thursday, citing people familiar with the matter.

Dec 07 2017

BRIEF-Sucampo reports Q3 GAAP earnings per share $0.19

* Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S

Nov 01 2017

BRIEF-Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA

* Sucampo Pharmaceuticals announces FDA acceptance of sNDA for amitiza in children with pediatric functional constipation, with priority review designation

Sep 28 2017

BRIEF-Cancer Prevention Pharmaceuticals receives $9.5 mln in additional funding from Sucampo

* Cancer Prevention Pharmaceuticals receives $9.5 million in additional funding from sucampo following phase 3 trial progress

Sep 11 2017

BRIEF-Sucampo Pharmaceuticals and Four Irvington Centre Associates enters into second amendment

* Sucampo Pharmaceuticals - On Sept 5, 2017, Co and Four Irvington Centre Associates, LLC entered into a second amendment to lease agreement- SEC filing

Sep 08 2017

BRIEF-Sucampo reports Q2 GAAP loss per share $3.92

* Q2 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

Aug 02 2017

BRIEF-Sucampo Pharmaceuticals says board voted to increase authorized size of board from six to seven

* Sucampo Pharmaceuticals Inc - On July 15 co's board voted to increase authorized size of board by one, from six to seven Source text: [http://bit.ly/2tgJFdK] Further company coverage:

Jul 19 2017

Earnings vs. Estimates